Innovation

In today’s pharmacy environment, many cost containment approaches are losing their effectiveness. These strategies can help employers maximize their pharmacy benefits and reduce costs.

Data needs vary from brand to brand. It’s critical for pharma brands to employ customized copay analytics strategies for their patient access programs.

By understanding your contract, communicating with your PBM, and working with a partner to craft your pharmacy strategy, you’ll be well prepared for the rise of biosimilar drugs.

How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.

In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?

The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.

If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?

6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?

Watch Truveris’ exclusive Human Resources round table, originally recorded on June 8th, 2022.

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

Truveris announces the launch of oneRx, the only drug price transparency solution that helps members navigate their pharmacy benefits.

After you procure a strong PBM contract, make sure your members are engaging with the plan productively.

By framing your pharmacy benefits strategy around these three pillars, you’ll construct a more cost-effective, accessible pharmacy program.

While a pharmacy benefits contract is a powerful lever for managing spend, it is also very complicated, with variables impacted by market and industry dynamics.

Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?

What is member-centricity? Why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?

Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.

Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.  

Why type of plan sponsor could benefit from carving out their pharmacy plan?